Skip to main content

Table 1 (abstract P109). The designs of LEVO-CTS and LICORN studies

From: 39th International Symposium on Intensive Care and Emergency Medicine

  LEVO-CTS, N=849 LICORN, N=335
Isolated CABG surgery 66.3% (563/849) 73.4% (246/335)
Combined CABG & valve(s) OR valve(s) only surgery 33.7% (286/849) 26.6% (89/335)
Preoperative LVEF limit for enrollment ≤35% ≤40%
Dose of levosimendan 0.2 micg/kg/min for 1 h, followed by 0.1 for 23 h 0.1 mic/kg/min for 24 h
Longest follow-up 90 days 180 days